153 related articles for article (PubMed ID: 36090218)
1. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers.
Tian Z; Yang Y; Wu H; Chen Y; Jia H; Zhu L; He R; Jin Y; Zhou B; Ge C; Sun Y; Yang Y
Heliyon; 2022 Aug; 8(8):e10410. PubMed ID: 36090218
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.
Yang Y; Tian Z; Guo R; Ren F
Oxid Med Cell Longev; 2020; 2020():9867595. PubMed ID: 32765809
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
4. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
5. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
7. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Sambade MJ; Kimple RJ; Camp JT; Peters E; Livasy CA; Sartor CI; Shields JM
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):575-81. PubMed ID: 20457354
[TBL] [Abstract][Full Text] [Related]
9. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
10. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
11. The novel dithiocarbamate, DpdtC suppresses HER2-overexpressed cancer cells by up-regulating NDRG1 via inactivation of HER2-ERK 1/2 signaling.
Yang Y; Liu Y; Guo R; Fu Y; Zhang Z; Zhang P; Zhou P; Wang T; Huang T; Li X; Li C
Sci Rep; 2018 Feb; 8(1):3398. PubMed ID: 29467385
[TBL] [Abstract][Full Text] [Related]
12. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
13. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
De Luca A; D'Alessio A; Gallo M; Maiello MR; Bode AM; Normanno N
Cell Cycle; 2014; 13(1):148-56. PubMed ID: 24200972
[TBL] [Abstract][Full Text] [Related]
14. Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
Sang X; Li L; Rui C; Liu Y; Liu Z; Tao Z; Cheng H; Liu P
Cancer Lett; 2021 Oct; 518():82-93. PubMed ID: 34153400
[TBL] [Abstract][Full Text] [Related]
15. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
16. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
17. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells.
Ye M; Huang W; Liu R; Kong Y; Liu Y; Chen X; Xu J
Front Pharmacol; 2021; 12():651516. PubMed ID: 34290605
[TBL] [Abstract][Full Text] [Related]
19. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ
Oncotarget; 2017 Oct; 8(49):85120-85135. PubMed ID: 29156708
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
